SPOTLIGHT: Baxter bullish on Gammagard


Baxter International says that a preliminary analysis of data from a Phase II study of Gammagard for Alzheimer's has produced enough encouraging signs to lay the groundwork for Phase III. The next study should get underway in early 2008. Release